Ua hoʻokō ka mea maʻi ʻAukekulelia i ka pane mua kupaianaha me ka lāʻau lapaʻau Dual CD19/CD20 CAR-T a BIOOCUS Medical Group no ka DLBCL i hoʻihoʻi ʻia

Ua ʻike ʻia ʻo Rodney Charles Monger, he kanaka 68 makahiki mai Australia mai, he maʻi nui maʻamau. Lymphoma Pūnaewele B (DLBCL) ʻekolu mau makahiki ma mua. I ka ʻimi ʻana i ka mālama kiʻekiʻe, ua huli ʻo ia i ka BIOOCUS Medical Group i ʻAukake 2025. Ua hōʻoia kahi biopsy cervical lymph node i ka lymphoma B-cell invasive o ke kikowaena germinal. Ua maikaʻi loa ka Immunohistochemistry no CD20, CD19, a me CD10, me ka hōʻike kiʻekiʻe o Bcl-6, Bcl-2 (70%+), a me c-MYC (60%+). Ua hōʻike ka hoʻāʻo genetic i ka hoʻonohonoho hou ʻana o BCL2 e FISH a me nā mutations ma EZH2, KMT2D, TNFRSF14, NRAS, a me TPMT genes—nā māka maopopo o kahi ʻano hoʻouka kaua a kiʻekiʻe.

Ma hope o ka loaʻa ʻana o ka pola i hui pū ʻia me kahi mea hoʻopaʻa BTK a me lenalidomide, a ukali ʻia e ka chemotherapy lymphodepletion FC, ua noho paʻakikī ka maʻi o Mr. Monger. Ua ʻōlelo ka hui ma BIOOCUS Medical Group i kā lākou lāʻau lapaʻau hou ʻo CD19/CD20 CAR-T cell.

Ma ka lā 8 o Kepakemapa, 2025, ua loaʻa iā Mr. Monger ka hoʻokomo ʻia ʻana o nā pūnaewele autologous CD19/CD20 CAR-T. ʻO ka mea kupanaha, ʻaʻole ʻo ia i ʻike i ka cytokine release syndrome (CRS) a me ka ʻole o ka immune effector cell-associated neurotoxicity syndrome (ICANS), e hopena ana i kahi papa hana maʻalahi ma hope o ka hoʻokomo ʻana i mālama iā ia i ka paʻa a me ka manaʻolana mai ka lā mua.

Ua hōʻike ka nānā ʻana i ke koko peripheral i ka hoʻonui kupaianaha ʻana o nā cell CAR-T, e hōʻoia ana i ka engraftment maikaʻi loa a me ka hoʻonui ʻana. I ka lā 4 ma hope o ka hoʻokomo ʻana, ʻo nā cell CAR19+ he 0.50% o nā cell CD3+ T (waiwai piha 6.04 × 10⁷/L) a me nā cell CAR20+ 0.41% (4.96 × 10⁷/L). I ka lā 7, ua piʻi ʻo CAR19+ i 1.68% (1.40 × 10⁷/L) a me CAR20+ i 1.63% (1.36 × 10⁷/L). I ka lā 10, ua hōʻea ʻo CAR19+ i 31.43% o nā cell CD3+ T (waiwai piha 3.13 × 10⁸/L) a ua hōʻea ʻo CAR20+ i 32.74% (waiwai piha 3.26 × 10⁸/L). Ua hōʻike hou aku ka cytometry kahe i ka hoʻolaha kaulike ma waena o nā CD4+ a me CD8+ subsets me ka hōʻike CAR pālua ikaika, e hōʻike ana i ka hiki o ka lāʻau lapaʻau ke hoʻolaha i ka hoʻomau a me ka hoʻonui ʻana i loko o vivo.

Ma ka nānā hou loa ʻana (lā 10), ke hoʻomau nei ʻo Mr. Monger i ka hana maikaʻi ma ke ʻano lapaʻau. Aia ʻo ia ma kahi papa hana lāʻau waha i hana kūikawā ʻia e pili ana i ka acyclovir, ka hui sulfamethoxazole, orelabrutinib, lenalidomide, a me nā mea kākoʻo, me ka nānā mau ʻana i nā helu koko, ka hana o ke akepaʻa a me nā puʻupaʻa, a me nā māka mumū.

Ua hāʻawi aku ka hui BIOOCUS Medical Group i ke kākoʻo piha a i kau ʻia ma ke kikowaena o ka mea maʻi ma nā wahi a pau, me ka noho ʻoluʻolu, nā meaʻai momona, ke kōkua halihali, a me ke aʻoaʻo noʻonoʻo no Mr. Monger a me kona ʻohana. Ua ʻae kēia ʻano holoʻokoʻa iā ia e kālele piha i ka hoʻōla ʻana.

Hōʻike ka hihia o Mr. Monger i ka hiki ke hoʻololi i ka lāʻau lapaʻau pālua CD19/CD20 CAR-T a BIOOCUS Medical Group no nā poʻe maʻi me ka DLBCL relapsed/refractory. ʻO ka hoʻonui wikiwiki a ikaika o nā cell CAR-T me ka ʻole o nā ʻawaʻawa koʻikoʻi e hōʻike ana i ka ʻaoʻao palekana maikaʻi o ka huahana a me ka hana anti-tumor ikaika—ʻoiai i kahi mea maʻi ʻelemakule me nā hiʻohiʻona molekala kiʻekiʻe.